KUBICZKOVÁ, Lenka, Lenka SEDLAŘÍKOVÁ, Roman HÁJEK and Sabina ŠEVČÍKOVÁ. TGF-beta - an excellent servant but a bad master. Journal of Translational Medicine. London, United Kingdom: BioMed Central, 2012, vol. 10, "art. 183", p. "nestrankovano", 24 pp. ISSN 1479-5876. doi:10.1186/1479-5876-10-183.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name TGF-beta - an excellent servant but a bad master
Authors KUBICZKOVÁ, Lenka (203 Czech Republic, belonging to the institution), Lenka SEDLAŘÍKOVÁ (203 Czech Republic, belonging to the institution), Roman HÁJEK (203 Czech Republic, guarantor, belonging to the institution) and Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution).
Edition Journal of Translational Medicine, London, United Kingdom, BioMed Central, 2012, 1479-5876.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.459
RIV identification code RIV/00216224:14110/12:00061365
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1186/1479-5876-10-183
UT WoS 000311108500001
Keywords in English TGF-beta; SMAD proteins; Oncogene; Suppressor; Solid tumors; Leukemia; Multiple myeloma
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 2. 1. 2013 23:56.
The transforming growth factor (TGF-beta) family of growth factors controls an immense number of cellular responses and figures prominently in development and homeostasis of most human tissues. Work over the past decades has revealed significant insight into the TGF-beta signal transduction network, such as activation of serine/threonine receptors through ligand binding, activation of SMAD proteins through phosphorylation, regulation of target genes expression in association with DNA-binding partners and regulation of SMAD activity and degradation. Disruption of the TGF-beta pathway has been implicated in many human diseases, including solid and hematopoietic tumors. As a potent inhibitor of cell proliferation, TGF-beta acts as a tumor suppressor; however in tumor cells, TGF-beta looses anti-proliferative response and become an oncogenic factor. This article reviews current understanding of TGF-beta signaling and different mechanisms that lead to its impairment in various solid tumors and hematological malignancies.
MSM0021622434, plan (intention)Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
NT11154, research and development projectName: Úloha mitotické disrupce v B lymfocytech u mnohočetném myelomu
Investor: Ministry of Health of the CR
PrintDisplayed: 16. 8. 2022 20:39